Clinical trials: Relapsed/ Refractory Multiple Myeloma
Multiple Myeloma and Plasma Cell Neoplasm
PAD. ICORG 05-01, V11
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as doxorubicin and dexamethasone, work in different ways to stop the growth of…
- Trial name
- NCT00814541
- Testing
- Bortezomib, Doxorubicin, Dexamethasone
- Where
- 9 sites in Ireland, United Kingdom
- Volunteers
- 53 people
- Sponsor
- Cancer Trials Ireland
Multiple Myeloma
Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma
Multiple myeloma (MM) is a neoplastic expansion of bone marrow plasma cells. Despite advances in treatment in recent years, MM is still a fatal disease.
- Trial name
- MYELOMA-HCQ (NCT04163107)
- Testing
- Hydroxychloroquine, Carfilzomib Injection, Dexamethasone
- Where
- 2 sites in Norway
- Volunteers
- 19 people
- Sponsor
- Norwegian University of Science and Technology
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma
RATIONALE: Giving high doses of chemotherapy drugs, such as busulfan and cyclophosphamide, before a donor bone marrow transplant helps stop the growth of cancer cells.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT01177371
- Testing
- busulfan, cyclophosphamide, allogeneic bone marrow transplantation
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Case Comprehensive Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm
Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome and melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00334932
- Testing
- bortezomib, melphalan, pegylated liposomal doxorubicin hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma
This research is being done to assess the effectiveness and safety of the combination of nivolumab with ixazomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.
- Trial name
- NCT04119336
- Testing
- Nivolumab, Ixazomib, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Andrew Yee, MD
Multiple Myeloma
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
This research study is studying a combination of study drugs as a possible treatment for relapsed and refractory Multiple Myeloma. The interventions involved in this study are elotuzumab, pomalidomide, bortezomib, dexamethasone.
- Trial name
- NCT02718833
- Testing
- Elotuzumab, Pomalidomide, Bortezomib
- Where
- 6 sites in United States
- Volunteers
- 52 people
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
- Trial name
- TRIlogy-4 (NCT07258511)
- Testing
- JNJ-79635322, Teclistamab
- Where
- 157 sites in United States, Australia and 13 more
- Volunteers
- 400 people
- Sponsor
- Janssen Research & Development, LLC
Hematological Malignancies
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to characterize the safety of Talquetamab and to determine the recommended Phase 2 dose(s) (RP2Ds) and dosing schedule assessed to be safe for Talquetamab (Part 1 [Dose Escalation]) and to further…
- Trial name
- MonumenTAL-1 (NCT03399799)
- Testing
- Talquetamab
- Where
- 13 sites in United States, Belgium and 2 more
- Volunteers
- 279 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
Primary Objectives: Phase I: To evaluate safety and tolerability of isatuximab in Japanese participants with relapsed and refractory multiple myeloma.
- Trial name
- Islands (NCT02812706)
- Testing
- Isatuximab SAR650984
- Where
- 13 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Sanofi
Relapsed/Refractory Multiple Myeloma
Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma
The purpose of this study is to assess safety, efficacy, pharmacokinetic (PK)/pharmacodynamic (PD), and immunogenicity with ISB 1342 in subjects with relapsed/refractory multiple myeloma.
- Trial name
- NCT03309111
- Testing
- ISB 1342
- Where
- 20 sites in United States, France
- Volunteers
- 81 people
- Sponsor
- Ichnos Sciences SA
Multiple Myeloma
Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma
This is a Phase 1, multicenter, open-label study o evaluate the safety and efficacy of CART-BCMA in subjects with relapsed/refractory multiple myeloma.
- Trial name
- NCT05346198
- Testing
- CART-BCMA
- Where
- 2 sites in China
- Volunteers
- 15 people
- Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
Multiple Myeloma
An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
The purpose of this study is to determine if adding Elotuzumab to Pomalidomide and low-dose dexamethasone is a more effective treatment of relapsed and refractory multiple myeloma compared to pomalidomide and low-dose…
- Trial name
- NCT02654132
- Testing
- Elotuzumab, Pomalidomide, Dexamethasone
- Where
- 55 sites in United States, Australia and 9 more
- Volunteers
- 117 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma
Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma
BMS will conduct a regulatory postmarketing surveillance (PMS) to evaluate the safety of elotuzumab in clinical practice in Japan.
- Trial name
- NCT02976493
- Testing
- No Intervention
- Where
- Japan
- Volunteers
- 500 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4…
- Trial name
- NCT05028348
- Testing
- Selinexor, Elotuzumab, Pomalidomide
- Where
- 20 sites in France, Germany and 2 more
- Volunteers
- 117 people
- Sponsor
- European Myeloma Network B.V.
Multiple Myeloma
Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma
To determine the maximum tolerated dose (MTD), if present, and dose schedule of ACY-1215 (ricolinostat) in combination with pomalidomide and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma.
- Trial name
- NCT02189343
- Testing
- ACY-1215 in combination with pomalidomide and dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Celgene
Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma
Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
This phase I trial studies the side effects and best dose of filanesib when given together with carfilzomib in treating patients with multiple myeloma or plasma cell leukemia that has returned or does not respond to treatment.
- Conditions
- Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT01372540
- Testing
- Carfilzomib, Filanesib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed/Refractory Multiple Myeloma
Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Third-line or Above Treatment
This study is a single-arm, single-center clinical study, with the main purpose of IIT clinical trials to evaluate the safety and initial efficacy of BCMA-GPRC5DCAR-T cells in subjects with relapsed/refractory multiple myeloma…
- Trial name
- r/r MM (NCT07195617)
- Testing
- BCMA-GPRC5D CART
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd
Multiple Myeloma
A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR
CC-5013-PASS-TR/A non-interventional, multi-center, observational post authorization safety study of patients with relapsed/refractory multiple myeloma treated with Lenalidomide in Turkey.
- Trial name
- NCT02387879
- Where
- 38 sites in Turkey (Türkiye)
- Volunteers
- 500 people
- Sponsor
- Celgene
Relapsed or Refractory Multiple Myeloma
Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM
The purpose of this study is to evaluate the safety and efficacy of mitoxantrone hydrochloride liposome injection in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT05052970
- Testing
- Mitoxantrone Hydrochloride Liposome injection, Bortezomib for Injection, Dexamethasone Acetate Tablets
- Where
- China
- Volunteers
- 60 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Multiple Myeloma
A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma
This is an open-label, multicenter study to confirm the safety and efficacy of durvalumab + daratumumab (D2) in subjects with relapsed and refractory multiple myeloma.
- Trial name
- FUSIONMM-003 (NCT02807454)
- Testing
- Daratumumab, Durvalumab, Pomalidomide
- Where
- 64 sites in United States, Belgium and 7 more
- Volunteers
- 37 people
- Sponsor
- Celgene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.